HomeCompareREPH vs PEP

REPH vs PEP: Dividend Comparison 2026

REPH yields 95.69% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REPH wins by $3.12M in total portfolio value
10 years
REPH
REPH
● Live price
95.69%
Share price
$2.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.26M
Annual income
$1,067,397.24
Full REPH calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — REPH vs PEP

📍 REPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREPHPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REPH + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REPH pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REPH
Annual income on $10K today (after 15% tax)
$8,133.97/yr
After 10yr DRIP, annual income (after tax)
$907,287.65/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, REPH beats the other by $854,693.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REPH + PEP for your $10,000?

REPH: 50%PEP: 50%
100% PEP50/50100% REPH
Portfolio after 10yr
$1.70M
Annual income
$564,636.46/yr
Blended yield
33.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

REPH
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Altman Z
-1.1
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REPH buys
0
PEP buys
0
No recent congressional trades found for REPH or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREPHPEP
Forward yield95.69%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$3.26M$141.9K
Annual income after 10y$1,067,397.24$61,875.67
Total dividends collected$2.90M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: REPH vs PEP ($10,000, DRIP)

YearREPH PortfolioREPH Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$20,269$9,569.38$10,849$509.42+$9.4KREPH
2$39,816$18,127.60$11,969$750.47+$27.8KREPH
3$75,882$33,279.13$13,500$1,124.14+$62.4KREPH
4$140,469$59,275.00$15,680$1,721.66+$124.8KREPH
5$252,850$102,548.32$18,929$2,715.34+$233.9KREPH
6$443,065$172,515.34$24,023$4,450.80+$419.0KREPH
7$756,599$282,519.41$32,510$7,669.92+$724.1KREPH
8$1,260,443$450,881.99$47,709$14,093.60+$1.21MREPH
9$2,050,673$701,999.14$77,415$28,083.48+$1.97MREPH
10$3,261,617$1,067,397.24$141,922$61,875.67+$3.12MREPH

REPH vs PEP: Complete Analysis 2026

REPHStock

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Full REPH Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this REPH vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REPH vs SCHDREPH vs JEPIREPH vs OREPH vs KOREPH vs MAINREPH vs MOREPH vs PMREPH vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.